The Anesthetic Effect and Safety of Dexmedetomidine in Cesarean Section: A Meta-Analysis

Gang Pang,1 Yuanmao Zhu,2 Yan Zhou,3 and Shanshan Tong1

1Department of Anesthesiology, Chongqing University Jiangjin Hospital, School of Medicine, Chongqing University, Chongqing, China
2Department of Painology, Chongqing University Jiangjin Hospital, School of Medicine, Chongqing University, Chongqing, China
3Department of Obstetrics and Gynecology, Chongqing University Jiangjin Hospital, School of Medicine, Chongqing University, Chongqing, China

Correspondence should be addressed to Yan Zhou; 252897862@qq.com and Shanshan Tong; tongshanshanjyy@126.com

Gang Pang and Yuanmao Zhu contributed equally to this work.

Received 11 March 2022; Revised 19 April 2022; Accepted 20 April 2022; Published 14 May 2022

Academic Editor: Sandip K. Mishra

Copyright © 2022 Gang Pang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To evaluate the anesthetic effect and safety of dexmedetomidine in cesarean section. Methods. The Cochrane Library, EMBASE, and PubMed databases (established until September 2020) were searched by computer. Two authors independently screened and extracted literature related to the application of dexmedetomidine in the cesarean section according to inclusion and exclusion criteria. The control group received either subarachnoid block (lumbar anesthesia) or combined lumbar anesthesia and epidural anesthesia (combined lumbar epidural anesthesia) with bupivacaine or combined bupivacaine and fentanyl. The observation group was additionally given dexmedetomidine based on the control group, to analyze the anesthetic effect and safety of dexmedetomidine in cesarean section. Results. A total of 580 cesarean delivery women were included in 8 studies, and the results showed that the peak time of sensory block in the observation group was shorter than that in the control group (standard mean difference = -0.28; 95% confidence interval: -0.48, -0.08; P = 0.006), sensory block lasted longer than that in the control group (standard mean difference = 1.49; 95% confidence interval: 1.21, 1.78; P < 0.00001), the sedation rate was higher than that in the control group, the onset of the first postoperative pain was significantly delayed compared with that in the control group, and the incidence of postoperative pain, nausea and vomiting, postoperative chills, and fever was lower than that in the control group (P < 0.05). Conclusion. Dexmedetomidine combined with lumbar anesthesia or combined lumbar epidural anesthesia for women in cesarean section has more clinical benefits and better safety.

1. Introduction

Cesarean section is a relatively common surgical method in clinical practice [1]. After a cesarean section, women are generally accompanied by strong incision pain and uterine involution pain, which not only affects their postoperative recovery but also leads to a sympathetic nervous response in patients, thereby promoting the secretion of catecholamines which inhibits the release of prolactin, which in turn affects lactation [2], which in turn affects the growth and development of neonates [3]. Therefore, perfect analgesia must be given after cesarean section. At present, the most ideal analgesia after cesarean section not only needs to achieve effective analgesia but also must minimize the impact on mother and baby [4].

The choice of anesthesia methods and anesthetic drugs has a great influence on the recovery of cesarean section women. Subarachnoid block (spinal anesthesia) or combined spinal-epidural anesthesia (spinal-epidural anesthesia) has a precise analgesic effect. It has the advantages of complete nerve block and is widely used in the cesarean section [5]. The duration of analgesia after spinal anesthesia is short, and patients after cesarean section spinal anesthesia often experience visceral pain, nausea, vomiting, and other adverse
reactions [6]. Although bupivacaine can prolong the sensory and motor block time, the postoperative analgesic effect is still unsatisfactory. Therefore, adjuvant analgesic and sedative drugs are often added to the spinal anesthesia to prolong the postoperative analgesic effect [7]. Combined spinal-epidural anesthesia is often added with adjuvant drugs to improve postoperative analgesia and promote early ambulation; at the same time, adjuvant drugs reduce the dose of bupivacaine, which can reduce the occurrence of adverse reactions after anesthesia [8]. Fentanyl can be used as an adjuvant drug for spinal anesthesia to prolong postoperative analgesia. It has the characteristics of fast peaking, a strong analgesic effect, and a short half-life. It is widely used in postoperative intravenous analgesia, but it can cause many adverse reactions, such as nausea, vomiting, urinary retention, and respiratory depression [9]. At the same time, maternal anxiety, chills, nausea, and vomiting are prone to adverse reactions during cesarean section [10]. Studies have shown that intraoperative use of a certain dose of dexmedetomidine (intravenous infusion started after the fetus is born) to assist sedation can prevent the onset of chills and significantly reduce maternal uterine contraction due to drugs [11]. The incidence of adverse reactions such as nausea and vomiting caused by the use of the puerperium and the surgical traction reaction is conducive to maintaining the stability of the intraoperative circulation and does not affect breathing, while the puerperal has stable breathing and circulation [12]. It will be beneficial to the blood perfusion of important organs such as the heart, brain, and kidney and produce a certain organ protection effect, which will help improve the safety and comfort of the mother during the operation [13]. Dexmedetomidine is a novel highly selective adrenergic receptor agonist, which is a selective adrenergic α2 receptor agonist. With its high selectivity and high efficacy, dexmedetomidine has great advantages in analgesia and sedation, and its hemodynamic stability can be used as an adjunct to spinal anesthesia [14, 15]. A large number of studies have also shown that fentanyl/bupivacaine combined with dexmedetomidine for intravenous analgesia after cesarean section can enhance the analgesic effect, reduce the number of analgesic drugs, and reduce the incidence of drug-related adverse reactions, to improve patient satisfaction [16, 17]. However, there is still a lack of clear evidence on the anesthesia effect and safety of dexmedetomidine in cesarean section of the parturient.

2. Materials and Methods

2.1. Inclusion and Exclusion Criteria. Inclusion criteria: randomized controlled trial with full English text. Included patients were adults (>18 years old), cesarean delivery women, American Society of Anesthesiologists (ASA) rating
| Study (year) | Age (years, $x \pm s$) | Operation time (min, $x \pm s$) | Experimental group ($n$) | Control group ($n$) |
|-------------|----------------------|-------------------------------|--------------------------|----------------------|
| Hanoura (2013) [18] | 29.8 ± 4.6 | 49 ± 8 | 2 ml of spinal anesthesia 0.5% bupivacaine+10 ml of epidural injection 0.25% bupivacaine+dexmedetomidine 1 $\mu$/kg and fentanyl 100 $\mu$g ($n = 25$) | 2ml of lumbar anesthesia 0.5% bupivacaine+10 ml of epidural injection 0.25% bupivacaine+fentanyl 100 $\mu$g (25) |
| Li (2015) [19] | 30.30 ± 3.81 | 45.89 ± 8.95 | Lumbar anesthesia 10 mg bupivacaine+10 $\mu$g dexmedetomidine (21) | Lumbar anesthesia 10 mg bupivacaine (21) |
| Liu (2015) [20] | 31 ± 5 | 39.1 ± 6.3 | 1.5 ml of lumbar anesthesia 0.5% bupivacaine+0.5$\mu$/kg dexmedetomidine (40); 1.5 ml of lumbar anesthesia 0.5% bupivacaine+1$\mu$/kg dexmedetomidine (40) ($n = 80$) | 1.5ml of lumbar anesthesia 0.5% bupivacaine+20 ml of 0.9% sodium chloride injection ($n = 40$) |
| Nasseri (2017) [21] | 32.16 ± 5.24 | 51.04 ± 19.39 | Lumbar anesthesia 12.5 mg 0.5% bupivacaine+5 $\mu$g dexmedetomidine (25) | Lumbar anesthesia 12.5 mg 0.5% bupivacaine+0.5 ml of 0.9% sodium chloride injection (25) |
| Sun (2015) [22] | 29.75 ± 4.90 | 42.89 ± 9.25 | 2 ml of lumbar anesthesia 0.5% bupivacaine+5 $\mu$g dexmedetomidine (25) | 2 ml of lumbar anesthesia 0.5% bupivacaine+1.0 ml of 0.9% sodium chloride injection (30) |
| Yousef (2015) [23] | 28.5 ± 5.7 | 50.4 ± 4.9 | 1.5 ml of spinal anesthesia 0.5% bupivacaine+10 ml of epidural infusion 0.25% bupivacaine+1 ml of dexmedetomidine 0.5 WG/kg+1 ml of fentanyl 50 $\mu$g (40) | 1.5 ml of spinal anesthesia 0.5% bupivacaine+10 ml of epidural injection 0.25% bupivacaine+1 ml of 0.9% sodium chloride injection+1 ml of fentanyl 50 $\mu$g (40) |
| Qi (2016) [24] | 29.75 ± 3.87 | 39.46 ± 7.81 | 2 ml of 0.5% bupivacaine containing 5 $\mu$g of dexmedetomidine ($n = 40$) | 2 ml of 0.5% bupivacaine alone ($n = 40$) |
| Xia (2018) [25] | 25.5 ± 3.5 | 45 ± 7.5 | Bupivacaine+5 mcg dexmedetomidine (45) | Bupivacaine+the same volume of saline (45) |
3.2 Basic Characteristic of the Included Literature. Eight studies with a total of 580 cesarean sections were included in this study (Figure 1). The characteristics of the included literature are listed in Table 1.

3.3 Risk of Bias Assessment. Figure 2 shows that the included studies have varying degrees of risk of bias.

3.4 Anesthesia Blocking Effect. Six studies [18, 19, 22–25] reported the time to peak sensory block level. There was significant heterogeneity among the studies, a fixed effect model was used for analysis. P<0.05 means the difference is statistically significant.

2.5 Statistical Analysis. The dichotomous variable effect index was expressed by relative risk (RR) and its 95% confidence interval (95% CI); the continuous variable effect index was expressed by standard mean difference (SMD) and its 95% CI. Heterogeneity was quantified using I² and X² tests. If I² ≥ 50%, P<0.1 indicates statistical heterogeneity, and the source of heterogeneity should be sought at this time. Sensitivity analysis can be used when necessary to test the stability of the results. If I² < 50%, P<0.1, indicating that there is no heterogeneity among the studies, a fixed effect model was used for analysis.
| Study or subgroup | Experimental | Control | Std. Mean difference | Std. Mean difference |
|------------------|--------------|---------|----------------------|----------------------|
|                  | Mean SD Total | Mean SD Total | IV, fixed, 95% Cl | IV, fixed, 95% Cl |
| Hanoura 2013     | 9.1 1.4 25   | 9.4 1.7 25 | -0.19 (-0.75, 0.37) |                      |
| Li 2015          | 8.1 3.55 21 | 8.9 3.52 21 | -0.22 (-0.83, 0.38) |                      |
| Qi 2016          | 5.54 1.12 39| 5.69 1.08 39 | -0.13 (-0.58, 0.31) | -0.28 (-0.79, 0.23) |
| Sun 2015         | 8.1 3.55 30 | 9.1 3.52 30 | -0.15 (-0.79, 0.43) |                      |
| Xia 2018         | 11.7 4 36   | 13.7 4.8 36 | -0.45 (-0.92, 0.02) |                      |
| Yousef 2015      | 7.5 1.5 40  | 8.1 1.7 40  | -0.37 (-0.81, 0.07) |                      |
| Total (95% Cl)   | 191 191 100.0% | -0.28 (-0.48, -0.08) |                      |

Favours experimental  Favours control

**Figure 3:** Forest plot of the peak time of sensory block plane.

| Study or subgroup | Experimental | Control | Std. Mean difference | Std. Mean difference |
|------------------|--------------|---------|----------------------|----------------------|
|                  | Mean SD Total | Mean SD Total | IV, fixed, 95% Cl | IV, fixed, 95% Cl |
| Li 2015          | 225.73 47.88 21 | 152.26 21.09 21 | 1.95 (1.26, 2.70) |                      |
| Qi 2016          | 253.21 42.79 39 | 188.33 37.62 39 | 1.59 (1.08, 2.11) |                      |
| Sun 2015         | 211.73 51.88 30 | 155.26 23.09 30 | 1.39 (0.82, 1.96) |                      |
| Xia 2018         | 110.3 35.3 36   | 67.5 31.2 36   | 1.27 (0.76, 1.78) |                      |
| Total (95% Cl)   | 126 126 100.0% | 1.49 (1.21, 1.78) |                      |

Heterogeneity : $\chi^2 = 3.44$, $df = 5$ ($P = 0.99$) $I^2 = 0$
Test for overall effect: $Z = 2.29$ ($P = 0.02$)

Favours experimental  Favours control

**Figure 4:** Forest plot of duration of sensory block.

| Study or subgroup | Experimental | Control | Std. Mean difference | Std. Mean difference |
|------------------|--------------|---------|----------------------|----------------------|
|                  | Mean SD Total | Mean SD Total | IV, fixed, 95% Cl | IV, fixed, 95% Cl |
| Hanoura 2013     | 126.7 2.9 25 | 115.6 2.7 25 | 0.39 (-0.17, 0.95) |                      |
| Li 2015          | 128.55 28.9 21 | 124.5 25.7 21 | 0.15 (-0.46, 0.75) |                      |
| Qi 2016          | 226.15 40.51 39 | 162.18 25.31 39 | 1.88 (1.34, 2.41) |                      |
| Sun 2015         | 128.55 28.9 30 | 127.5 25.7 30 | 0.04 (-0.47, 0.54) |                      |
| Xia 2018         | 224.9 45.4 36   | 155.1 31.2 36   | 1.77 (1.22, 2.31) |                      |
| Yousef 2015      | 148 36 40      | 133.5 40 40    | 0.38 (-0.06, 0.82) |                      |
| Total (95% Cl)   | 191 191 100.0% | 0.76 (0.11, 1.42) |                      |

Heterogeneity : $\chi^2 = 4.57$, $df = 5$ ($P < 0.00001$) $I^2 = 89$
Test for overall effect: $Z = 2.29$ ($P = 0.02$)

Favours experimental  Favours control

**Figure 5:** Forest plot of recovery of motor block.

| Study or subgroup | Experimental | Control | Risk ratio | Risk ratio |
|------------------|--------------|---------|------------|------------|
|                  | Events Total | Events Total | M–H, fixed, 95% Cl | M–H, fixed, 95% Cl |
| Hanoura 2013     | 21 25 | 10 25 | 2.10 (1.26, 3.50) |                      |
| Xia 2018         | 32 36 | 19 0 | Not estimable |                      |
| Yousef 2015      | 32 40 | 23 40 | 1.39 (1.02, 1.89) |                      |
| Total (95% Cl)   | 101 65 100.0% | 1.61 (1.23, 2.10) |                      |

Total events 75 52
Heterogeneity : $\chi^2 = 1.90$, $df = 1$ ($P = 0.17$) $I^2 = 47$
Test for overall effect: $Z = 3.48$ ($P = 0.0005$)

Favours experimental  Favours control

**Figure 6:** Forest plot of sedation rate.
no significant heterogeneity among the studies \((P = 0.94, I^2 = 0\%))

, and the fixed effect model was used for analysis. The results showed that the peak time of the sensory block plane in the observation group was shorter than that in the control group \((\text{SMD} = -0.28; 95\% \text{ CI: } -0.48, -0.08; \ P = 0.006)\) (Figure 3). Four studies [19, 22, 24, 25] reported duration of sensory block. There was no significant heterogeneity among the studies \((P = 0.49, I^2 = 0\%))

, and the fixed effect model was used for analysis.
There was no significant heterogeneity among the studies \((P < 0.001, I^2 = 89\%\)) and the results showed that the recovery time of motor block between the two groups was statistically significant \((SMD = 0.71; 95\% CI: 0.11, 1.42; P = 0.02)\) (Figure 5).

### 3.5. Sedation

Three studies \([18, 23, 25]\) reported on intraoperative sedation. There was no significant heterogeneity among the studies \((P < 0.001, I^2 = 96\%)\). The random effects model was used for analysis. The results showed that the first postoperative pain attack in the observation group was significantly delayed compared with the control group \((SMD = 4.68, 95\% CI: 2.26-7.10, P < 0.001)\) (Figure 7). One study \([18]\) reported the incidence of postoperative pain, and the results showed that the incidence of postoperative pain in the observation group was significantly lower than that in the control group \((R = 0.25, 95\% CI: 0.08-0.78, P = 0.02)\).

### 3.6. Postoperative Analgesia

Five studies \([18, 19, 22, 24, 25]\) reported the time to the first postoperative pain attack. There was significant heterogeneity among the studies \((P < 0.001, I^2 = 96\%)\). The random effects model was used for analysis. The results showed that the first postoperative pain attack time in the observation group was significantly delayed compared with the control group \((SMD = 4.68, 95\% CI: 2.26-7.10, P < 0.001)\) (Figure 6). One study \([18]\) reported the incidence of postoperative pain, and the results showed that the incidence of postoperative pain in the observation group was significantly lower than that in the control group \((R = 0.25, 95\% CI: 0.08-0.78, P = 0.02)\).

### 3.7. Adverse Reactions

Eight studies reported the incidence of postoperative adverse reactions. The results showed that the incidence of nausea and vomiting, postoperative chills, and fever in the observation group was lower than that in the control group \((P < 0.05)\). Other adverse reactions in the two groups were hypotension, bradycardia, and itching. There was no significant difference in the incidences of dizziness, intraoperative pain, urinary retention, diarrhea, and headache \((P > 0.05)\) (Table 2).

### 3.8. Publication Bias

Funnel plot analysis was conducted on 8 articles reporting hypotension, and the results showed that the funnel plot was symmetric, so the bias was not obvious (Figure 8).

### 4. Discussion

For cesarean section anesthesia, subarachnoid or epidural injection of local anesthetics such as bupivacaine or ropivacaine or opioids is often the option of choice \([5]\). On this basis, adjuvant systemic sedative drugs may help to improve the effect of anesthesia and reduce the occurrence of adverse reactions \([26]\). Dexmedetomidine is an auxiliary sedative commonly used in clinical practice and is also widely used in cesarean section anesthesia. However, the effects of dexmedetomidine on the anesthetic effect and adverse reactions of the cesarean section under lumbar anesthesia or combined lumbar epidural anesthesia have not been determined \([27, 28]\). This meta-analysis showed that intravenous dexmedetomidine-assisted sedation based on lumbar anesthesia or combined lumbar epidural anesthesia could achieve better analgesic and sedative effects. Dexmedetomidine can shorten the peak time and prolong the duration of the sensory block. It can significantly delay the onset of the first postoperative pain and reduce the incidence of postoperative pain. In addition, the incidence of hypotension and bradycardia did not increase after the addition of dexmedetomidine, indicating that it did not lead to instability in hemodynamics. But it reduced the incidence of nausea, vomiting, chills, and fever. The risk bias of included studies in this system evaluation is low, and selection bias may affect the results of the study.

Dexmedetomidine has the advantages of sensory block and analgesia. On the one hand, due to its effect at the spinal cord level, it inhibits the release of norepinephrine and blocks the transmission of pain signals to the brain by acting on A2 receptors in the presynaptic membrane and posterior membrane of the spinal cord \([29]\). On the other hand, due to its effect on the A2 receptor of the cerebral vena cava, it inhibits the excitation of the neurons in the vena cava and blocks the pain nerve signal transduction pathway of the medullary globus-spinal cord to achieve sedation and analgesia \([30]\). Studies have found that in patients undergoing abdominal and lower limb surgery, epidural anesthesia with dexmedetomidine shortens the onset time of sensory block and prolongs postoperative analgesia time. Some studies have also proved that the analgesic effect of dexmedetomidine is superior to clonidine in vaginal hysterectomy or children’s lower abdominal surgery \([31-33]\). By acting on the central nervous system, dexmedetomidine can affect the activities of sympathetic and parasympathetic nerves, accelerate gastrointestinal emptying and peristalsis, reduce the stimulation of the gastrointestinal tract stretch to the vomiting center, and thus reduce the incidence of nausea and vomiting. Dexmedetomidine inhibits the central temperature regulation system and reduces the perioperative stress response caused by elevated adrenaline, thus reducing the occurrence of chills \([34, 35]\).

The advantage of this study lies in the systematic retrieval of relevant literature, two-person literature screening, and data extraction, which reduces the systematic error in the operation process. At the same time, the risk of bias in the included literature was low, and the meta-analysis had good homogeneity, so the results were relatively reliable. The shortcoming of the study is that due to the few kinds of research in related fields and the small sample size, the results may be inaccurate, thus affecting the real effect of the results. Therefore, the systematic evaluation shows that dexmedetomidine can bring more clinical benefits to patients based on lumbar anesthesia or combined lumbar epidural anesthesia. However, due to the small sample size, clinicians should be cautious in this conclusion. At present, there are few studies in this field, and it is urgent to confirm with a large sample of randomized controlled trials.
5. Conclusion

Dexmedetomidine combined with lumbar anesthesia or combined lumbar epidural anesthesia for women in cesarean section has more clinical benefits and better safety.

Data Availability

The data used to support this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Gang Pang and Yuanmao Zhu contributed equally to this work.

References

[1] C. Antoine and B. K. Young, "Cesarean section one hundred years 1920-2020: the good, the bad and the ugly," Journal of Perinatal Medicine, vol. 49, no. 1, pp. 5–16, 2020.
[2] F. Zhang, J. Cheng, S. Yan, H. Wu, and T. Bai, "Early feeding behaviors and breastfeeding outcomes after cesarean section," Breastfeeding Medicine, vol. 14, no. 5, pp. 325–333, 2019.
[3] J. Sandall, R. M. Tribe, L. Avery et al., "Short-term and long-term effects of caesarean section on the health of women and children," Lancet, vol. 392, no. 10155, pp. 1349–1357, 2018.
[4] C. D. Sutton and B. Carvalho, "Optimal pain management after cesarean delivery," Anesthesiology Clinics, vol. 35, no. 1, pp. 107–124, 2017.
[5] N. L. Fernandes and R. A. Dyer, "Anesthesia for urgent cesarean section," Clinics in Perinatology, vol. 46, no. 4, pp. 785–799, 2019.
[6] N. A. G. Gomez, N. Warren, Y. Labko, and D. R. Sinclair, "Intrathecal opioid dosing during spinal anesthesia for cesarean section: an integrative review," Journal of Doctoral Nursing Practice, vol. 13, no. 2, pp. 108–119, 2020.
[7] M. Martin-Flores, J. C. Anderson, D. M. Sakai et al., "A retrospective analysis of the epidural use of bupivacaine 0.0625–0.125% with opioids in bitches undergoing cesarean section," The Canadian Veterinary Journal, vol. 60, no. 12, pp. 1349–1352, 2019.
[8] O. M. Shah and K. M. Bhat, "Comparison of the efficacy and safety of morphine and fentanyl as adjuvants to bupivacaine in providing operative anesthesia and postoperative analgesia in subumblical surgeries using combined spinal epidural technique," Anesthesia, Essays and Researches, vol. 11, no. 4, pp. 913–920, 2017.
[9] W. P. P. Ferrarezi, A. F. A. Braga, V. B. Ferreira et al., "Spinal anesthesia for elective cesarean section. Bupivacaine associated with different doses of fentanyl: randomized clinical trial," Brazilian Journal of Anesthesiology, vol. 71, no. 6, pp. 642–648, 2021.
[10] M. Balki and J. C. Carvalho, "Intraoperative nausea and vomiting during cesarean section under regional anesthesia," International Journal of Obstetric Anesthesia, vol. 14, no. 3, pp. 230–241, 2005.
[11] L. Bautista and R. B. George, "Dexmedetomidine for every cesarean delivery...maybe not?,” Canadian Journal of Anaesthesia, vol. 66, no. 7, pp. 751–754, 2019.
[12] K. Lato, I. B. Bekes, P. Widorschwendter et al., "Hypotension due to spinal anesthesia influences fetal circulation in primary cesarean sections," Archives of Gynecology and Obstetrics, vol. 297, no. 3, pp. 667–674, 2018.
[13] M. A. Karahan, S. Yalcin, H. Aydogan et al., "Curcumin and dexmedetomidine prevents oxidative stress and renal injury in hind limb ischemia/reperfusion injury in a rat model," Renal Failure, vol. 38, no. 5, pp. 693–698, 2016.
[14] M. Mahmoud and K. P. Mason, "Dexmedetomidine: review, update, and future considerations of paediatric perioperative and periprocedural applications and limitations," British Journal of Anaesthesia, vol. 115, no. 2, pp. 171–182, 2015.
[15] Z. J. Carr, T. J. Cios, K. F. Potter, and J. T. Swick, "Does dexmedetomidine ameliorate postoperative cognitive dysfunction? A brief review of the recent literature," Current Neurology and Neuroscience Reports, vol. 18, no. 10, p. 64, 2018.
[16] L. Liu, J. Qian, B. Shen, F. Xiao, and H. Shen, "Intrathecal dexmedetomidine can decrease the 95% effective dose of bupivacaine in spinal anesthesia for cesarean section: a prospective, double-blinded, randomized study," Medicine (Baltimore), vol. 98, no. 9, 2019.
[17] B. Abdul Hadi, S. M. Sbeitan, and A. K. Shacky, "Fentanyl vs fentanyl-dexmedetomidine in lumbar foraminotomy surgery," Therapeutics and Clinical Risk Management, vol. 15, no. 15, pp. 885–890, 2019.
[18] S. E. Hanoura, R. Hassanan, and R. Singh, "Intraoperative conditions and quality of postoperative analgesia after adding dexmedetomidine to epidural bupivacaine and fentanyl in elective cesarean section using combined spinal-epidural anesthesia," Anesthesia, Essays and Researches, vol. 7, no. 2, pp. 168–172, 2013.
[19] Z. Li, M. Tian, C. Y. Zhang et al., "A randomised controlled trial to evaluate the effectiveness of intrathecal bupivacaine combined with different adjuvants (fentanyl, clonidine and dexmedetomidine) in cesarean section," Drug Research, vol. 65, no. 11, pp. 581–586, 2015.
[20] Y. Liu, H. X. Chen, D. L. Kang, X. H. Kuang, W. X. Liu, and J. Ni, "Influence of dexmedetomidine on incidence of adverse reactions introduced by hemabate in postpartum hemorrhage during cesarean section," International Journal of Clinical and Experimental Medicine, vol. 8, no. 8, p. 13776-82, 2015.
[21] K. Nasser, N. Ghadimi, and B. Nouri, "Effects of intrathecal dexmedetomidine on shivering after spinal anesthesia for cesarean section: a double-blind randomized clinical trial," Drug Design, Development and Therapy, vol. 11, no. 11, pp. 1107–1113, 2017.
[22] Y. Sun, Y. Xu, and G. N. Wang, "Comparative evaluation of intrathecal bupivacaine alone, bupivacaine-fentanyl, and bupivacaine-dexmedetomidine in cesarean section," Drug Res (Stuttg.), vol. 65, no. 9, pp. 468–472, 2015.
[23] A. A. Yousef, H. A. Salem, and M. Z. Moustafa, "Effect of mini-dose epidural dexmedetomidine in elective cesarean section using combined spinal-epidural anesthesia: a randomized double-blinded controlled study," Journal of Anesthesia, vol. 29, no. 5, pp. 708–714, 2015.
[24] X. Qi, D. Chen, G. Li et al., "Comparison of intrathecal dexmedetomidine with morphine as adjuvants in cesarean sections,"
[25] F. Xia, X. Chang, Y. Zhang, L. Wang, and F. Xiao, “The effect of intrathecal dexmedetomidine on the dose requirement of hyperbaric bupivacaine in spinal anaesthesia for caesarean section: a prospective, double-blinded, randomized study,” BMC Anesthesiology, vol. 18, no. 1, p. 74, 2018.

[26] R. Alizadeh and Z. A. Fard, “Renal effects of general anesthesia from old to recent studies,” Journal of Cellular Physiology, vol. 234, no. 10, pp. 16944–16952, 2019.

[27] M. Yu, C. Han, X. Jiang, X. Wu, L. Yu, and Z. Ding, “Effect and placental transfer of dexmedetomidine during caesarean section under general anaesthesia,” Basic & Clinical Pharmacology & Toxicology, vol. 117, no. 3, pp. 204–208, 2015.

[28] K. Kart and A. Hanci, “Effects of remifentanil and dexmedetomidine on the mother’s awareness and neonatal Apgar scores in caesarean section under general anaesthesia,” Journal of International Medical Research, vol. 46, no. 5, pp. 1846–1854, 2018.

[29] M. Momeni, C. Khalifa, G. Lemaire et al., “Propofol plus low-dose dexmedetomidine infusion and postoperative delirium in older patients undergoing cardiac surgery,” British Journal of Anaesthesia, vol. 126, no. 3, pp. 665–673, 2021.

[30] T. H. Chiu, M. J. Chen, Y. R. Yang, J. J. Yang, and F. I. Tang, “Action of dexmedetomidine on rat locus coeruleus neurones: intracellular recording in vitro,” European Journal of Pharmacology, vol. 285, no. 3, pp. 261–268, 1995.

[31] P. Szmuk, D. Andropoulos, F. McGowan et al., “An open label pilot study of a dexmedetomidine-remifentanil-caudal anesthetic for infant lower abdominal/lower extremity surgery: the T REX pilot study,” Paediatric Anaesthesia, vol. 29, no. 1, pp. 59–67, 2019.

[32] M. E. Erbatur, Ş. C. Sezen, A. C. Bayraktar, M. Arslan, M. Kavutçu, and M. E. Aydı̇n, “Effects of dexmedetomidine on renal tissue after lower limb ischemia reperfusion injury in streptozotocin induced diabetic rats,” Libyan Journal of Medicine, vol. 12, no. 1, p. 1270021, 2017.

[33] M. U. Santpur, G. M. Kahalekar, N. Saraf, and A. Losari, “Effect of intravenous dexmedetomidine on spinal anaesthesia with 0.5% hyperbaric bupivacaine in lower abdominal surgeries: a prospective randomized control study,” Anesth Essays Res, vol. 10, no. 3, pp. 497–501, 2016.

[34] C. L. Tang, J. Li, Z. T. Zhang et al., “Neuroprotective effect of bispectral index-guided fast-track anesthesia using sevoflurane combined with dexmedetomidine for intracranial aneurysm embolization,” Neural Regeneration Research, vol. 13, no. 2, pp. 280–288, 2018.

[35] R. Ben-Abraham, D. Ogorek, and A. A. Weinbroum, “Dexmedetomidine: a promising agent for anesthesia and perioperative care,” The Israel Medical Association Journal, vol. 2, no. 10, pp. 793–796, 2000.